Skip to main content

Table 3 Risk ratio (RR) of progression according to each biomarker

From: Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

MarkerProgressionNo progressionTotal
≤ 3 months≤ 6 monthsAnytime after marker appearance
ESR1 mutation
n (%)10 (56%)14 (78%)18 (100%)0 (0%)18 (100%)
 RR (ref = non mut)4.9 [3.0–8.0]3.3 [2.4–4.5]1.9 [1.7–2.0] 
> 25% CA-15.3 increase
n (%)12 (60%)14 (70%)18 (90%)2 (10%)20 (100%)
 RR (ref = no increase)5.9 [3.8–9.2]3.4 [2.5–4.8]2.0 [1.7–2.4] 
> 100% CA-15.3 increase
n (%)2 (50%)2 (50%)2 (50%)2 (50%)4 (100%)
 RR (ref = no increase)4.0 [1.5–11.0]2.2 [0.8–5.8]1.1 [0.4–2.8] 
> 25% DNA increase
n (%)14 (18%)22 (29%)45 (58%)32 (42%)77 (100%)
 RR (ref = no increase)1.6 [0.8–3.3]1.1 [0.7–1.7]0.9 [0.7–1.2] 
> 100% DNA increase
n (%)8 (19%)13 (31%)20 (48%)22 (52%)42 (100%)
 RR (ref = no increase)1.4 [0.7–2.7]1.1 [0.6–1.7]0.8 [0.6–1.2]